Aramark (ARMK) Director Reports 210.525 Dividend-Equivalent Units

Stephen I. Sadove, a director of Aramark (ARMK), reported an internal transaction dated 08/20/2025 showing acquisition of 210.525 dividend-equivalent rights related to deferred stock units at a $0 price.

Rhea-AI Filing Summary

Stephen I. Sadove, a director of Aramark (ARMK), reported an internal transaction dated 08/20/2025 showing acquisition of 210.525 dividend-equivalent rights related to deferred stock units at a $0 price. After the transaction he beneficially owned 94,042.121 shares directly and 15,000 shares indirectly through a trust. The filing explains these dividend-equivalent rights vest on the same schedule as the underlying awards. The Form 4 was signed by an attorney-in-fact on 08/21/2025.

Insights

Corporate Governance Expert

TL;DR Director received dividend-equivalent units that vest with existing deferred awards; ownership change appears routine and non-cash.

The reported acquisition of 210.525 dividend-equivalent rights at no cash cost reflects typical compensation mechanics for deferred stock units rather than an open-market trade. With total direct beneficial ownership of 94,042.121 shares and 15,000 indirectly held via trust, the incremental change is small relative to the existing holdings and does not indicate a change in control or a financing event. Documentation explicitly ties vesting of these rights to the schedules of underlying awards, which limits additional interpretive uncertainty.

Securities Compliance Analyst

TL;DR Filing documents a routine Section 16 disclosure of accrued dividend equivalents; timing and form comply with Form 4 requirements.

The Form 4 discloses a non-derivative acquisition code 'A' for dividend-equivalent rights that accrued on deferred stock units. The zero price and the explanation indicate these were not purchased but issued as compensation-related credits. The form shows the filer is a director and the report was filed singly. Signature by attorney-in-fact is present and dated 08/21/2025, satisfying execution disclosure conventions.

Insider Trade Summary

Grant/Award: 210.525 shares

Grant/Award 2 txns

Insider SADOVE STEPHEN I

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	210.525	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 94,042.121 shares (Direct); Common Stock — 15,000 shares (Indirect, By Trust)

Footnotes (1)

1. F1. Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2025 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SADOVE STEPHEN I

(Last) (First) (Middle)

C/O ARAMARK

2400 MARKET STREET

(Street)

PHILADELPHIA PA 19103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aramark [ ARMK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		A		210.525(1)	A	$0	94,042.121	D
Common Stock								15,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the reporting person on deferred stock units held by the reporting person. These dividend equivalent rights vest on the same schedules as the underlying awards.

Remarks:

	/s/ Ryan S. Spengler, as Attorney-in-fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.